In an entirely African-American cohort, we compared clinical characteristics, cardiac structure and function, and all-cause mortality in patients with heart failure (HF) with preserved ejection fraction (HFpEF) in relation to patients with heart failure with reduced ejection fraction (HFrEF) and those without HF.
Background
African Americans are at increased risk for HF. Nevertheless, there are limited phenotypic and prognostic data in African Americans with HFpEF compared with those with HFrEF and those without HF.
Methods
Middle-aged African Americans from the Jackson, Mississippi, cohort of the ARIC (Atherosclerosis Risk In Communities) study (n ¼ 2,445) underwent echocardiography between 1993 and 1995. HF prevalence was available in 1,962 patients for whom left ventricular ejection fraction (LVEF) could be quantified. Participants with HF were categorized as having HFpEF (LVEF !50%), HFrEF (LVEF <50%), or no HF, with comparisons made between groups.
Results

HF was identified in 116 (5.9%) participants (HFpEF n ¼ 85 [73%]; HFrEF n ¼ 31 [27%]
). Compared with those without HF, those with HFpEF were older, were more likely to be female, and had more frequent comorbidities and concentric hypertrophy. In relation to HFrEF, those with HFpEF were more likely to be female but less likely to have coronary heart disease, diabetes mellitus, chronic kidney disease, left atrial enlargement, and eccentric hypertrophy. Over a median 13.7 years of follow-up, risk of death differed between groups, with age-and sex-adjusted hazard ratios of 1.51 (95% confidence interval: 1.01 to 2.25) for HFpEF versus those without HF and 2.50 (95% confidence interval: 1.37 to 4.58) for HFrEF versus HFpEF.
Conclusions
In this cohort of middle-aged African Americans, HFpEF was the most common form of HF and was associated with a substantially better prognosis than HFrEF but worse than those without HF. African Americans, as compared with other racial groups, are at increased risk for the development of heart failure (HF) (1) (2) (3) . Additionally, HF in African Americans occurs at a younger age and is associated with a higher prevalence of cardiovascular risk factors, particularly hypertension and diabetes mellitus, but lower frequency of coronary heart disease (CHD) (4) (5) (6) . It has been suggested that the prevalence of heart failure and preserved ejection fraction (HFpEF) may be higher in African Americans than current estimates of HFpEF in the general population (5, 7, 8) . However, findings are mixed regarding survival in African Americans with HF (3, 4, 6, 9) , and information is limited concerning prognosis in African Americans with HFpEF (10, 11) . We therefore aimed to describe differences in clinical characteristics, cardiac structure and function, and prognosis in a community-based sample of African Americans with HFpEF as compared with those with heart failure and reduced ejection fraction (HFrEF) and those without HF.
Methods
Study population. The ARIC (Atherosclerosis Risk In Communities) study is an ongoing, prospective observational study of the natural history of atherosclerotic diseases and cardiovascular risk factors. Detailed study rationale, design, and procedures have been previously published (12) . The original cohort was recruited between 1987 and 1989 using probability sampling of middle-age (45 to 64 years) men and women from 4 communities in the United States (Forsyth County, North Carolina; Jackson, Mississippi; Minneapolis, Minnesota; and Washington County, Maryland). The Jackson field center enrolled an entirely AfricanAmerican cohort. Subsequent follow-up visits occurred at 3-year intervals up to 1998, with annual telephone interviews conducted between visits. Institutional review boards from each site approved the study, and informed consent was obtained from all participants.
Transthoracic echocardiography was only performed in the Jackson, Mississippi, cohort during visit 3 (1993 to 1995). Of 2,445 participants who underwent transthoracic echocardiography, 1,962 were included in this analysis after sequential exclusion of 318 in whom left ventricular ejection fraction (LVEF) could not be calculated, 32 with missing HF status, 3 in whom incident HF occurred after visit 3 but before the echocardiogram, and 130 with missing covariate data. Echocardiography. Two-dimensional (2-D), M-mode, and Doppler images were acquired with an Acuson 128XP/10c cardiac ultrasound machine with 2.5-, 3.5-, and 5.0-MHz transducers (Malvern, Pennsylvania). Quality control measures have been previously described (13) . LV end-diastolic diameter, LV end-systolic diameter, and septal and posterior wall thicknesses were measured from 2-D images according to American Society of Echocardiography criteria. LV mass was calculated using the simplified cubed equation and indexed (LVMI) to height (m 2.7 ) with left ventricular hypertrophy (LVH) defined as LVMI !51 g/m 2.7 (14) . Relative wall thickness was calculated as 2 Â posterior wall thickness/LV end-diastolic diameter, with 0.42 considered normal. LVEF was calculated using the 2-D Teichholz method, with LVEF !50% and <50% defining preserved and reduced LVEF, respectively. Diastolic dysfunction was determined based upon transmitral Doppler E to A ratio, with 0.75 or >1.5 considered abnormal (15) . Definition of HF. Prevalent HF at visit 3 was defined by: 1) stage 3 or manifest HF according to Gothenburg criteria or the use of medications for HF at visit 1 (n ¼ 82); or 2) hospitalization with International Classification of DiseasesNinth Revision (ICD-9) code for HF (428.x) listed at discharge between visit 1 and 3 (n ¼ 34) (3). The Gothenburg criteria are a validated scoring system composed of 3 componentsdcardiac, pulmonary, and therapydin which stage 3 or manifest HF requires 1 point from each component (16) . Participants with quantifiable LVEF by echocardiography and prevalent HF were categorized as HFpEF (LVEF !50%) or HFrEF (LVEF <50%). Covariates. Established definitions for hypertension, obesity, diabetes mellitus, CHD, stroke, smoking status, and medication use were used as previously described in the ARIC study (17) . Electrocardiographic LVH was determined by Cornell criteria. Pulmonary disease was defined as self-reported history of physician-diagnosed lung disease or asthma. Retinopathy, estimated glomerular filtration rate, ankle brachial index, hematologic parameters, lipids, and glucose were measured according to standardized protocols, with chronic kidney disease (CKD) and peripheral arterial disease defined as previously described (12, (18) (19) (20) . Ankle brachial index was available in 1,239 participants. All covariates were ascertained at visit 3, except for hemoglobin, white blood cell count, and creatinine, for which the most recent previous measures were used. Outcome. The primary outcome was death from any cause. The follow-up period was defined as the time elapsed from the date of echocardiography to the date of death, date of last contact for those lost to follow-up, or December 31, 2008. Deaths were ascertained through annual phone calls to participants and ongoing surveillance of health department certificate files. Statistical methods. For each of the 3 groups (no HF, HFpEF, and HFrEF), summary statistics for covariates were calculated as counts and percentages and medians and interquartile ranges for categorical and continuous data, respectively. Comparisons were then made between: 1) HFpEF and no HF; and 2) HFpEF and HFrEF. Chisquare or Fisher exact test and Wilcoxon rank-sum test were used to compare baseline characteristics. All-cause mortality rates were calculated (number of deaths divided by person-time at risk). Survival analysis was performed according to the Kaplan-Meier method, with the log-rank test used to assess for differences. Univariable and multivariable hazard ratios for death were estimated using Cox proportional hazards regression. Covariates included in multivariable models included age, sex, LVEF, and clinical characteristics. Propensity scores for HFpEF versus no HF and HFrEF versus HFpEF were calculated using clinical characteristics that significantly differed in univariate analyses between groups. The propensity score was then included in Cox proportional hazards models. Two-sided p values <0.05 were considered significant. Analyses were performed using Stata version 11.2 (Stata Corp., College Station, Texas). 
Results
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HFpEF in African Americans in the ARIC Study no differences with regard to heart rate or blood pressure. As expected, symptoms of HF, such as orthopnea, paroxysmal nocturnal dyspnea, and lower extremity edema, were more common among those with HF compared with those without HF (Table 1) .
Comorbidities were common among those with HFpEF (Table 1 ). In particular, hypertension, obesity, diabetes mellitus, pulmonary disease, peripheral arterial disease, and CHD were more frequent among those with HFpEF compared with those without HF. Of note, hypertension was highly prevalent, approaching 60%, even in those without HF. Comorbidities were also common among those with HFrEFdwith diabetes mellitus, CHD, and CKD present more frequently than in those with HFpEF.
Cardiac structure and function differed between groups (Table 2 ). Those with HFpEF had increased wall thickness and LVMI compared with those without HF, although prevalence of diastolic dysfunction and left atrial enlargement did not differ between these 2 groups. In contrast, those with HFrEF had the highest LV wall thickness and 
LVMI. Additionally, left atrial enlargement and mitral regurgitation were more frequent among those with HFrEF compared with those with HFpEF. Concentric hypertrophy was the most common LV geometry; however, it was significantly more frequent in patients with HFpEF compared with those without HF. Hypertrophy was present in nearly all participants with HFrEF, with eccentric hypertrophy more frequent in patients with HFrEF compared with those with HFpEF.
Over a median follow-up of 13.7 years, deaths occurred in 21%, 31%, and 61% of those without HF, with HFpEF, and with HFrEF, respectively (Table 3) . Death rates in patients with HFpEF were increased compared with those without HF but were lower than those with HFrEF, even when adjusted for age. In age-and sex-adjusted Cox proportional hazard models, risk of death differed among groups. HFpEF was associated with a 51% increased risk of death compared with no HF (hazard ratio [HR]: 1.51; 95% CI: 1.01 to 2.25). HFrEF was associated with the worst survival, with 2.5 times the risk of death compared with HFpEF (HR: 2.50; 95% CI: 1.37 to 4.58). When further adjusted for LVEF, HFpEF was associated with 61% increased risk of death as compared with no HF (HR: 1.61; 95% CI: 1.08 to 2.41). Adjustment for differences in clinical characteristics attenuated the mortality risk associated with HFpEF versus no HF; however, those with HFrEF remained at significantly increased risk of death compared with those with HFpEF ( Table 3 , Fig. 1 ).
Discussion
In a community-based sample of middle-age African Americans, we found that demographic and clinical characteristics as well as cardiac structure and function significantly differed among patients with HFpEF, HFrEF, and no HF. By comparing patients with HFpEF with those without HF, we found that older age, female sex, hypertension, obesity, diabetes mellitus, and concentric hypertrophy were more common in patients with HFpEF. Similarly, diabetes mellitus, CKD, CHD, and left atrial enlargement were more common in patients with HFrEF than those with HFpEF. Survival differed among groups, with HFpEF portending a worse prognosis than no HF but not as severe as HFrEF. Together, these findings suggest that in African Americans, HFpEF and HFrEF may be distinct syndromes.
Representation of African Americans in observational studies and clinical trials is typically low; thus, HF in this population is not well understood (21,22) . Moreover, few HF Gupta et al.
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HFpEF in African Americans in the ARIC Study studies focus specifically on African Americans (23) because most literature involving race in HF addresses differences among racial groups. This is in spite of a higher prevalence of cardiovascular risk factors and greater burden of HF among African Americans. The existing literature suggests that the development and progression of HF in African Americans may be characterized by predominantly nonischemic etiologies, more severe natural history, and possibly a different response to pharmacotherapy when compared with predominantly white studies (9, 21) . By evaluating an entirely African-American cohort, our findings may advance understanding of HF in this high-risk population.
Approximately three-quarters of African Americans with HF in our cohort had HFpEF. This is concordant with 2 population-based studies of patients with ambulatory HF in which 57% to 76% had preserved systolic function (7, 24) but differs from an ambulatory Veterans Administration population in which HFpEF was present in 25% (25) . However, only 6% of those in the Veterans Administration study were female; therefore, the Veterans Administration population may not be representative of the typical HFpEF population (25) . In comparison, 65% of the Jackson, Mississippi, cohort was female, which may be one explanation for the higher prevalence of HFpEF. Our findings are also consistent with population studies of patients with ambulatory HF that included multiple ethnicities and demonstrated a higher prevalence of HFpEF than HFrEF (26) (27) (28) . However, our results contrast with those of studies evaluating African Americans hospitalized with acute decompensated HF in which HFpEF was prevalent in 29% to 43% (5, 6, 29) , suggesting that the relative frequency of HFpEF and HFrEF may differ between hospitalized and ambulatory settings (30) . Additionally, the finding that HFpEF was more common than HFrEF may be explained, in part, by the high prevalence of hypertension and relatively low frequency of CHD.
Regardless of preserved or reduced LVEF, comorbidities were common in HF. However, the pattern of clinical characteristics differed between patients with HFpEF and those with HFrEF. In addition to diabetes mellitus and CKD, CHD was more frequent in patients with HFrEF compared with those with HFpEF, although it was only present in one-third of those with HFrEF despite the high prevalence of atherosclerotic risk factors. Overall, CHD was not as common in patients with HF as typically described in predominantly white populations, which may be partially explained by the relatively high proportion of female and middle-age patients in this study. Hypertension, however, was present in 85% of those with HF. Together, these findings suggest that hypertension, along with other comorbidities such as obesity, diabetes mellitus, and CKD, rather than CHD, may be relatively more important factors in HF in African Americans.
The most striking finding related to cardiac structure was the marked prevalence of LVH in those with HF and among those without HF. Although hypertension may be the most common contributor to hypertrophy, other factors including obesity Tables 1 and 2 .
Figure 1 Survival in African Americans According to HF Status
Kaplan-Meier survival analysis in those without heart failure (nonHF), HF with preserved ejection fraction (HFpEF), and those with HF and reduced ejection fraction (HFrEF).
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JACC: Heart Failure Vol. (4, 37) . In our analysis, these comorbidities were frequent in patients with HF, and a particularly worrisome finding was that concentric hypertrophy was present in 60% of those without HF. The high prevalence of hypertension and concentric LVH, a known marker of increased cardiovascular risk in African Americans (38) , portends a potential increase in HF among this group (39) .
There is also uncertainty regarding the risk of death in chronic HF among African Americans (5). Registries of hospitalized patients with HF suggest similar or better survival in African-American versus white patients (4) (5) (6) 40) . This is congruent with previous reports from the ARIC study demonstrating similar mortality rates between races at 30 days and 1 year; however, the longer follow-up time in the ARIC study revealed higher fatality rates in African Americans at 5 years post-HF hospitalization (3) . Few studies have evaluated survival in HFpEF in African Americans. In a predominantly male Veterans Administration population, survival over 5 years of follow-up did not differ according to race among those with HFpEF; however, among African Americans, HFpEF appeared to be associated with a similar or slightly better prognosis than HFrEF (10) . Results from the Duke Databank of Cardiovascular Disease suggest a better 5-year survival in patients with HFpEF (68%) (11) , as compared with those with HFrEF (51%) (41) , although a direct comparison of mortality between HFpEF and HFrEF in African Americans was not made.
We found that HFpEF was associated with a more benign prognosis than HFrEF. This is consistent with a metaanalysis of nearly 42,000 patients with HF that demonstrated a 32% lower risk of death in HFpEF compared with HFrEF, although stratification according to race was not reported (42) . It is also consistent with the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) trial (43) but differs from epidemiological data from Olmsted County, Enhanced Feedback for Effective Cardiac Treatment, and the Framingham Heart Study, in which mortality rates were similar between patients with HFpEF and those with HFrEF (44) (45) (46) . This may, in part, be explained by differences in study populations because those studies that capture patients during or immediately following an acute hospitalization find that HFpEF and HFrEF have similar mortality, particularly among the elderly (30) . In contrast, patients with ambulatory HF, such as those in the Cardiovascular Health and Strong Heart studies, which enrolled an older biracial population and Native Americans, respectively, demonstrated lower fatality rates in HFpEF versus HFrEF (26, 27) . However, representation of African Americans in these studies was generally low, limiting applicability to this race.
We also found the mortality rate in patients with HFpEF to be greater than that of those without HF. The risk of death in those with HFpEF was 61% higher than age-, sex-, and LVEF-matched participants without prevalent HF. However, adjustment for additional clinical characteristics attenuated this risk. It has been proposed that HFpEF is a collection of comorbidities and that the syndrome of HFpEF may not even exist (47) . In contrast, pooled analyses of clinical trials of HFpEF and cardiovascular trials of patients without HF have demonstrated higher mortality rates in patients with HFpEF compared with those without HF (48) . Our data in African Americans are consistent with these pooled analyses. Although adjustment for comorbidities attenuated this risk, the relatively small number of deaths in our HFpEF population limited our statistical power. Nevertheless, our findings highlight the importance of comorbidities in African Americans with HFpEF but do not mitigate the broader literature demonstrating that HFpEF is associated with a worse prognosis than no HF.
Recent literature also suggests that one-half of all deaths in HFpEF may not be related to cardiovascular causes (49) (50) (51) , again emphasizing the impact of comorbidities (37, 52) . We extended these findings by showing that noncardiovascular comorbidities were frequent among African Americans with HF. Furthermore, using ICD codes (recognizing their limitation in identifying cause of death), we observed a similar trend to previous reports, namely, that 58%, 44%, and 26% of deaths in those with no HF, HFpEF, and HFrEF, respectively, were due to noncardiovascular causes (Fig. 2) . Together, these findings emphasize the importance of treating comorbidities, particularly among those with HFpEF, as a potential approach to improving outcomes (37, 49, 52, 53) . Study limitations. Although we specifically evaluated an entirely African-American cohort over a long follow-up 
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HFpEF in African Americans in the ARIC Study period, limitations should be noted. The cross-sectional design precludes assessment of causality among clinical characteristics, cardiac structure and function, and HF. However, differences among patients with HFpEF, HFrEF, and no HF may provide insight into targets for future investigation. The definition for prevalent HF was based upon Gothenburg criteria and unadjudicated hospitalization ICD-9 codes, although these methods have been validated in the ARIC study (3, 54) . Importantly, this approach captured participants with previous or current symptoms of HF, as recommended by the American College of Cardiology/American Heart Association staging of HF (55). LVEF was not assessed at the time of incident HF, and it is possible that LVEF may have recovered between the incident HF event and our assessment. However, LVEF has previously been demonstrated to be similar between acute and chronic HF (56) . Moreover, our findings suggest that LVEF measured after incident HF still imparts prognostic information. The Teichholz method was used to calculate LVEF because volumetric measurements were not available. Diastolic function was assessed with transmitral Doppler E/A ratio because estimation of left atrial volumes, tissue Doppler imaging, transmitral E-wave deceleration time, pulmonary venous flow, and isovolumic relaxation time were not obtained at echocardiography. Although diastolic dysfunction is frequently reported in HFpEF, we found it to be present in only 25% of participants with HFpEF, which did not differ between patients with HFpEF and those without HF, likely reflecting limitations in diastolic assessment. There may have been selection bias with regard to participants who presented for echocardiography or had interpretable images, such that the sickest individuals, including those with more severe HF, may be underrepresented. Inherent to the ARIC study's design, this study included a selected age range and consisted entirely of African Americans from Jackson, Mississippi. Therefore, our results may not be generalizable to younger, more elderly, or all African Americans. However, the mean age of African Americans in most HF registries is 63 to 64 years, falling within the range of our cohort (4) (5) (6) 25) . The observed mortality rates may not be directly applicable to a more contemporary time period due to temporal changes in HF management. Finally, the relatively low numbers of participants with prevalent HF may limit statistical power.
Conclusions
We found in a community-based sample of middle-age African Americans that demographic and clinical characteristics, as well as cardiac structure and function, significantly differed among patients with HFpEF, HFrEF, and no HF. HFpEF was more common than HFrEF and portended a worse prognosis than no HF but not as severe as HFrEF. Because this population bears a disproportionate burden of HF, focused investigation on African Americans is an important step to understanding HF and developing strategies for prevention, detection, and treatment.
